Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CELU | PRESS-RELEASE | bearish | 6/10 | Celularity Inc. received a Nasdaq delisting notice due to its failure to file its 2025 Form 10-K on time. The company ha | Apr 17, 2026 |
| PYXS | PRESS-RELEASE | bullish | 7/10 | Pyxis Oncology announced preclinical data showing that a mouse analog of its drug MICVO (maMICVO) demonstrated dose-depe | Apr 17, 2026 |
| RVMD | PRESS-RELEASE | bearish | 7/10 | Revolution Medicines raised approximately $2.225 billion through a concurrent public offering of common stock and conver | Apr 17, 2026 |
| OLMA | PRESS-RELEASE | mixed | 5/10 | Olema Oncology released preclinical data showing palazestrant fully recruits the NCoR1 corepressor for complete estrogen | Apr 17, 2026 |
| CRDF | PRESS-RELEASE | bullish | 7/10 | Cardiff Oncology presented preclinical data at AACR 2026 showing that its PLK1 inhibitor onvansertib enhances the antitu | Apr 17, 2026 |
| XLO | PRESS-RELEASE | mixed | 5/10 | Xilio Therapeutics released preclinical data for XTX601, a masked T cell engager targeting CLDN18.2, demonstrating tumor | Apr 17, 2026 |
| ZNTL | PRESS-RELEASE | bullish | 7/10 | Zentalis Pharmaceuticals presented preclinical data at AACR 2026 showing azenosertib, its investigational WEE1 inhibitor | Apr 17, 2026 |
| EVAX | PRESS-RELEASE | bullish | 7/10 | Evaxion announced new Phase 2 data for its AI-designed personalized cancer vaccine EVX-01, showing 86% of vaccine target | Apr 17, 2026 |
| IMTX | PRESS-RELEASE | bullish | 7/10 | Immatics announced a deep and ongoing remission in a 17-year-old pediatric patient with advanced nephroblastoma after tr | Apr 17, 2026 |
| EVAX | PRESS-RELEASE | bullish | 7/10 | Evaxion announced new data from a collaboration with Duke University showing its AI-Immunology™ platform can identify en | Apr 17, 2026 |
| INKT | PRESS-RELEASE | bullish | 8/10 | MiNK Therapeutics announced positive Phase II trial data for its agenT-797 cell therapy in combination with botensilimab | Apr 17, 2026 |
| ZYME | PRESS-RELEASE | bullish | 7/10 | Zymeworks announced six preclinical poster presentations at AACR 2026 showcasing its next-generation antibody-drug conju | Apr 17, 2026 |
| RPRX | PRESS-RELEASE | neutral | 3/10 | Royalty Pharma announced a quarterly dividend of $0.235 per share, payable June 10, 2026, to shareholders of record as o | Apr 17, 2026 |
| VXRT | PRESS-RELEASE | neutral | 4/10 | Vaxart announced a $25 million at-the-market equity financing facility with Lincoln Park Capital, allowing the company t | Apr 17, 2026 |
| LYRA | PRESS-RELEASE | bearish | 8/10 | Lyra Therapeutics announced it will voluntarily file a Form 25 to delist its stock from Nasdaq, accelerating the deregis | Apr 17, 2026 |
| COGT | PRESS-RELEASE | bullish | 7/10 | Cogent Biosciences presented preclinical data at AACR 2026 for two pipeline candidates: CGT1263, a pan-KRAS(ON) inhibito | Apr 17, 2026 |
| UPB | PRESS-RELEASE | neutral | 3/10 | Upstream Bio announced two upcoming poster presentations at the ATS 2026 conference featuring Phase 2 VIBRANT trial data | Apr 17, 2026 |
| IMRN | PRESS-RELEASE | bullish | 6/10 | Immuron Limited reported unaudited Q3 sales of AUD$1.5 million, up 16% year-over-year, driven by strong growth in Austra | Apr 21, 2026 |
| KURA | PRESS-RELEASE | bullish | 8/10 | Kura Oncology announced preliminary clinical data from a subset of patients with clear cell renal cell carcinoma (ccRCC) | Apr 17, 2026 |
| TRVI | PRESS-RELEASE | neutral | 6/10 | Trevi Therapeutics priced an underwritten public offering of 11,600,000 shares at $13.00 per share, raising approximatel | Apr 16, 2026 |
| KLRA | PRESS-RELEASE | neutral | 6/10 | Kailera Therapeutics priced its initial public offering of 39,062,500 shares at $16.00 per share, raising $625 million i | Apr 16, 2026 |
| PACB | PRESS-RELEASE | neutral | 1/10 | PacBio announced it will report its Q1 2026 results on May 7, 2026. | Apr 16, 2026 |
| EBS | PRESS-RELEASE | neutral | 1/10 | Emergent BioSolutions announced it will report its Q1 2026 results on April 30, 2026. | Apr 16, 2026 |
| EBS | PRESS-RELEASE | bearish | 7/10 | Emergent BioSolutions announced a $150 million term loan refinancing with OrbiMed and an amended $50 million ABL facilit | Apr 16, 2026 |
| EVAX | PRESS-RELEASE | neutral | 2/10 | Evaxion held its Annual General Meeting, approving the 2025 Annual Report and re-electing four board members while addin | Apr 16, 2026 |
| ACHV | PRESS-RELEASE | bullish | 5/10 | Achieve Life Sciences announced a $354 million private placement financing, including $180 million upfront and up to $17 | Apr 16, 2026 |
| ARDX | PRESS-RELEASE | neutral | 1/10 | Ardelyx, Inc. announced it will report its Q1 2026 results on April 30, 2026. | Apr 16, 2026 |
| HELP | PRESS-RELEASE | neutral | 3/10 | Helus Pharma announced the appointment of Dr. Ken Kramer as Senior Vice President, Medical Affairs, bringing over two de | Apr 16, 2026 |
| MGTX | PRESS-RELEASE | bullish | 7/10 | MeiraGTx has reacquired global rights to botaretigene sparoparvovec (bota-vec) for XLRP from Johnson & Johnson for a $25 | Apr 16, 2026 |
| ANL | PRESS-RELEASE | neutral | 5/10 | Adlai Nortye Ltd. announced a $150 million private placement of 11,320,755 ADSs at $13.25 per share, priced at the April | Apr 16, 2026 |